ImmunoTherapyNews.net

Cancer immunotherapy

XagenaNewsletter
Medical Meeting
Xagena Mappa
Gastrobase.it

Search results for "Melanoma"

Immune-suppressing molecules such as PD-L1 can be co-opted by cancer cells to suppress the natural immune response to cancer. Upregulation of PD-L1 and inhibition of antitumor T-cell activation is obs ...


The anti-programmed death-1 ( PD-1 ) antibody Nivolumab ( Opdivo ) has clinical activity in patients with metastatic melanoma. Nivolumab plus vaccine was investigated as adjuvant therapy in resected ...


Nivolumab ( Opdivo ) was associated with higher rates of objective response than chemotherapy in a phase 3 study involving patients with Ipilimumab-refractory metastatic melanoma. The use of Nivolum ...


Adoptive cell therapy ( ACT ) for cancers using autologous tumor-infiltrating lymphocytes ( TILs ) can induce immune responses and antitumor activity in metastatic melanoma patients. Researchers a ...


Both Ipilimumab, an anti–cytotoxic T-lymphocyte–associated antigen 4 monoclonal antibody ( Yervoy ) and Nivolumab, an anti–programmed death 1 monoclonal antibody ( Opdivo ), have been approved by the ...


The results of the pivotal OPTiM study have shown that Talimogene laherparepvec monotherapy is the first oncolytic immunotherapy to demonstrate therapeutic benefit in a phase 3 trial for patients with ...


PD-1 antibody, Nivolumab ( Opdivo ), was administered with/without a multi-peptide vaccine to 126 patients ( pts ) with unresectable melanoma that failed at least one regimen and were Ipilimumab ( Yer ...


Nivolumab ( Opdivo ) is a programmed death-1 ( PD-1 ) immune checkpoint inhibitor which has shown durable tumor responses in multiple cancer types and prolongs overall survival in patients with melano ...


Uveal melanomas are a rare type of melanoma with only 5-7 cases per 1 million persons diagnosed each year. Patients with metastatic melanoma of uveal origin, tend to have lower response rates on tradi ...


Anti-PD-1 therapy has shown significant clinical activity in advanced melanoma and in other cancers. Factors predictive of response remain vaguely defined. Researchers have reported on clinical ch ...


Brain metastases develop in 40% of metastatic melanoma patients. Untreated brain metastases exclude from most clinical trials. In prior trials, treatment of metastatic melanoma with Pembrolizumab ( Ke ...


Immune-suppressing molecules such as PD-L1 can be co-opted by cancer cells to suppress the natural immune response to cancer. Upregulation of PD-L1 and inhibition of antitumor T-cell activation is obs ...


Strategies to help improve the efficacy of the immune system against cancer represent an important innovation, with recent attention having focused on anti-programmed death (PD)-1 / PD-ligand 1 (L1) m ...


The indoleamine 2,3-dioxygenase ( IDO ) pathway is a key counter-regulatory mechanism that normally inhibits immune responses when appropriate. In the setting of cancer, IDO pathway-mediated immune ...